Received Dec 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLUBLOK) | SANOFI PASTEUR | UNK | — | OT |
got the second dose due to a miscommunication with the patient believing they did not get the vaccine yet with no reported adverse event; Initial information received on 08-Dec-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 63 years old and unknown gender patient who got the second dose of Influenza Trivalent Recombinant Vaccine [Flublok] due to a miscommunication, believing they did not get the vaccine yet with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received 0.5mL of suspect Influenza Trivalent Recombinant Vaccine, Solution for injection (lot number, expiry date and strength not reported) via unknown route in unknown administration site for Immunisation and got the second dose due to a miscommunication with the patient believing they did not get the vaccine yet with no reported adverse event (inappropriate schedule of product administration) (latency same day). It was reported "A Clinic wanting to know were there any adverse reactions if two doses of Flublok were given 3-days apart". Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.